Pinato, David J.

Immunotherapies for hepatocellular carcinoma

Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,843

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 1,294

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Pinato, D. J., Howlett, S., Ottaviani, D., Urus, H., Patel, A., Mineo, T., Brock, C., Power, D., Hatcher, O., Falconer, A., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 626

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis

Cited by 275

Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.

Pinato, D. J., Murray, S. M., Forner, A., Kaneko, T., Fessas, P., Toniutto, P., Mínguez, B., Cacciato, V., Avellini, C., Diaz, A., et al. (2021) · Journal for ImmunoTherapy of Cancer

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 228

Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC

Rakaee, M., Adib, E., Ricciuti, B., Sholl, L. M., Shi, W., Alessi, J. V., Cortellini, A., Fulgenzi, C. A. M., Viola, P., Pinato, D. J., et al. (2023) · JAMA Oncology

Cancer Immunotherapy and BiomarkersAI in cancer detection

Cited by 141

Antibiotic therapy and outcome from immune-checkpoint inhibitors

Pinato, D. J., Gramenitskaya, D., Altmann, D. M., Boyton, R. J., Mullish, B. H., Marchesi, J. R., & Bower, M. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 116

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Ricciuti, B., Alessi, J. V., Elkrief, A., Wang, X., Cortellini, A., Li, Y. Y., Vaz, V. R., Gupta, H., Pecci, F., Barrichello, A., et al. (2022) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 112

NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy

Pinter, M., Pinato, D. J., Ramadori, P., & Heikenwalder, M. (2023) · Clinical Cancer Research

Liver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and Prognosis

Cited by 103

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 97

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., et al. (2024) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 90

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Pinato, D. J., Cortellini, A., Sukumaran, A., Cole, T., Pai, M., Habib, N., Spalding, D., Sodergren, M. H., Martinez, M., Dhillon, T., et al. (2021) · BMC Cancer

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 79

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma

Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 74

Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients

Pria, A. D., Pinato, D., Roe, J., Naresh, K., Nelson, M., & Bower, M. (2017) · Blood

Viral-associated cancers and disordersCytomegalovirus and herpesvirus research

Cited by 71

Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?

Hussain, N., Naeem, M., & Pinato, D. J. (2021) · Human Vaccines & Immunotherapeutics

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 69

Retinoic Acid Receptor‐β Is Downregulated in Hepatocellular Carcinoma and Cirrhosis and Its Expression Inhibits Myosin‐Driven Activation and Durotaxis in Hepatic Stellate Cells

Cortes, E., Lachowski, D., Rice, A., Chronopoulos, A., Robinson, B., Thorpe, S., Lee, D. A., Possamai, L. A., Wang, H., Pinato, D. J., et al. (2019) · Hepatology

Liver physiology and pathologyHepatocellular Carcinoma Treatment and Prognosis

Cited by 64

Evaluating the impact of COVID‐19 on supportive care needs, psychological distress and quality of life in UK cancer survivors and their support network

Hulbert‐Williams, N. J., Leslie, M., Hulbert‐Williams, L., Smith, E., Howells, L., & Pinato, D. J. (2021) · European Journal of Cancer Care

Cancer survivorship and careCOVID-19 and Mental Health

Cited by 34

Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma

D'Alessio, A., Pai, M., Spalding, D., Goldin, R. D., Scheiner, B., Korolewicz, J., Fulgenzi, C. A. M., Ward, C., Yip, V., Slater, S., et al. (2023) · Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 17